What Wall Street Thinks about BD after 1Q18 Earnings Release
BD’s latest analyst recommendations
Becton Dickinson (BDX) announced its 1Q18 earnings results on February 6, 2018. It registered robust revenues as well as earnings, exceeding analysts’ estimates. For details, read Becton Dickinson’s Fiscal 1Q18 Results Beat Analyst Estimates. The company also posted its updated fiscal 2018 guidance, which included its recently acquired Bard business as well. In this article, we’ll take a look at the latest analyst recommendations, ratings, and target prices for BD stock for the next one year.
Interested in ABT? Don't miss the next report.
Receive e-mail alerts for new research on ABT
As of February 12, 2018, according to a Reuters survey consisting of 19 investment research firms, 63% of analysts recommended BD as a “buy,” and 37% rated it as a “hold.”
As of February 12, 2018, BD stock has a consensus 12-month target price of $241.58, implying a 12-month return potential of ~11.3% on an investment in BD stock for the next 12 months. BD stock closed at $217.14 on February 9, 2018.
Recent recommendation revisions
Following BD’s 1Q18 earnings results announcement on February 6, 2018, a number of investment brokerages updated their recommendation on BD stock. On February 7, 2018, Morgan Stanley increased its price target on BD stock from $245 to $250. It has an “equal weight” rating on the stock. On February 6, 2018, Piper Jaffray reissued its “overweight” rating on BD stock with a price target of $260 per share.
Peers Medtronic (MDT), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) have average analyst 12-month target prices of $91.98, $243.56, and $68.22, respectively. These target prices imply a 12-month investment return potential of 15.7%, 21.7%, and 19.3%, respectively.